Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 417

1.

Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.

Elie R, Rüther E, Farr I, Emilien G, Salinas E.

J Clin Psychiatry. 1999 Aug;60(8):536-44.

PMID:
10485636
2.

Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group.

Fry J, Scharf M, Mangano R, Fujimori M.

Int Clin Psychopharmacol. 2000 May;15(3):141-52.

PMID:
10870872
3.

Zaleplon: a review of its use in the treatment of insomnia.

Dooley M, Plosker GL.

Drugs. 2000 Aug;60(2):413-45. Review.

PMID:
10983740
4.
6.

Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.

Zammit GK, Corser B, Doghramji K, Fry JM, James S, Krystal A, Mangano RM.

J Clin Sleep Med. 2006 Oct 15;2(4):417-23.

PMID:
17557470
7.

A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.

Scharf MB, Roth T, Vogel GW, Walsh JK.

J Clin Psychiatry. 1994 May;55(5):192-9.

PMID:
8071269
8.

Zolpidem for persistent insomnia in SSRI-treated depressed patients.

Asnis GM, Chakraburtty A, DuBoff EA, Krystal A, Londborg PD, Rosenberg R, Roth-Schechter B, Scharf MB, Walsh JK.

J Clin Psychiatry. 1999 Oct;60(10):668-76.

PMID:
10549683
9.

Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects.

Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M.

Prim Care Companion J Clin Psychiatry. 1999 Aug;1(4):114-120.

10.

Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon.

Stone BM, Turner C, Mills SL, Paty I, Patat A, Darwish M, Danjou P.

Br J Clin Pharmacol. 2002 Feb;53(2):196-202.

11.

Safety of zaleplon in the treatment of insomnia.

Israel AG, Kramer JA.

Ann Pharmacother. 2002 May;36(5):852-9. Review.

PMID:
11978165
12.

Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation.

Herrmann WM, Kubicki ST, Boden S, Eich FX, Attali P, Coquelin JP.

J Int Med Res. 1993 Nov-Dec;21(6):306-22.

PMID:
8143886
13.

Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia.

Weitzel KW, Wickman JM, Augustin SG, Strom JG.

Clin Ther. 2000 Nov;22(11):1254-67. Review.

PMID:
11117652
14.

Efficacy of L-846 in patients with insomnia: evaluation by polysomnography.

Sakamoto T, Uchimura N, Mukai M, Mizuma H, Shirakawa SI, Nakazawa Y.

Psychiatry Clin Neurosci. 1998 Apr;52(2):156-7.

15.

Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia.

Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW.

Clin Neuropharmacol. 2000 Jan-Feb;23(1):17-21.

PMID:
10682226
17.

Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group.

Sleep Med. 2006 Aug;7(5):397-406. Epub 2006 Jul 3.

PMID:
16815744
18.

Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.

Roehrs TA, Randall S, Harris E, Maan R, Roth T.

J Psychopharmacol. 2012 Aug;26(8):1088-95. doi: 10.1177/0269881111424455. Epub 2011 Oct 16.

19.

Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.

Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P.

Sleep Med. 2006 Jun;7(4):312-8. Epub 2006 May 18.

PMID:
16709464
20.

A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients.

Hajak G, Hedner J, Eglin M, Loft H, Stórustovu SI, Lütolf S, Lundahl J; Gaboxadol Study 99775 Group.

Sleep Med. 2009 Aug;10(7):705-12. doi: 10.1016/j.sleep.2008.09.010. Epub 2009 Apr 5.

PMID:
19346160

Supplemental Content

Support Center